

## Overview

### Useful For

Interpretation of CHF8P / Chromogenic Factor VIII Inhibitor Bethesda Profile, Plasma

Detecting the presence and titer of a specific factor inhibitor directed against coagulation factor VIII

This test is **not useful** for detecting the presence of inhibitors directed against other clotting factors and **will not** detect the presence of lupus anticoagulants.

### Method Name

Only orderable as part of a profile. For more information see CHF8P / Chromogenic Factor VIII Inhibitor Bethesda Profile, Plasma.

Medical Interpretation

### NY State Available

Yes

## Specimen

### Specimen Type

Plasma Na Cit

### Reject Due To

### Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Plasma Na Cit	Frozen	14 days	

## Clinical & Interpretive

### Clinical Information

Factor VIII (FVIII) inhibitors are IgG antibodies directed against coagulation FVIII that typically result in development of potentially life-threatening hemorrhage. These antibodies may be alloimmune: developing in patients with congenital FVIII deficiency (hemophilia A) in response to therapeutic infusions of factor VIII concentrate or autoimmune: occurring in patients without hemophilia (not previously factor VIII deficient) either spontaneously or during pregnancy or in association with autoimmune diseases.

**Reference Values**

Only orderable as part of a profile. For more information see CHF8P / Chromogenic Factor VIII Inhibitor Bethesda Profile, Plasma.

An interpretive report will be provided.

**Interpretation**

The interpretive report will include assay information, background information, and conclusions based on the test results.

**Cautions**

Contamination with excess heparin and hemodilution due to improper specimen collection through an intravenous access device or collection above a running intravenous fluid line may cause spurious results.

**Clinical Reference**

1. Peyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. *J Thromb Haemost*. 2016;14(2):248-261
2. Verbruggen B, van Heerde WL, Laros-van Gorkom BA. Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen. *Semin Thromb Hemost*. 2009;35(8):752-759
3. Miller C, Platt S, Rice A, Kelly F, Soucie JM, Hemophilia Inhibitor Research Study Investigators. Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. *J Thromb Haemost*. 2012;10:1055-1061

**Performance****Method Description**

A coagulation expert (clinician or hematopathologist) reviews the laboratory data, and an interpretive report is issued.

**PDF Report**

No

**Day(s) Performed**

Monday through Friday

**Report Available**

3 days

**Performing Laboratory Location**

Mayo Clinic Laboratories - Rochester Main Campus

**Fees & Codes**

**Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

**Test Classification**

Not Applicable

**CPT Code Information**

85390-26

**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
CH8BI	Chromogenic FVIII Inhibitor Interp	95122-8

Result ID	Test Result Name	Result LOINC® Value
606844	Chromogenic FVIII Inhibitor Interp	95122-8
606865	Reviewed by	18771-6